Global Healthcare Study on Psoriasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Psoriasis (PsO). Basic parameters: from 14 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Primary outcome measures
- Psoriasis Area Severity Index (PASI) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
Secondary outcome measures (5)
- Dermatology Life Quality Index (DLQI) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Nail Psoriasis Severity Index (NAPSI) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Numerical Rating Scale (NRS) for disease severity [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Physician Global Assessment (PGA) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Body Surface Area (BSA) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
Eligibility criteria
Inclusion criteria
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Psoriasis
Exclusion criteria
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- University of Zurich — Zurich
Publications
- Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv. PMID 38470165
- Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28. PMID 35988043
- Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128. PMID 36653920
- Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297. PMID 39459597
- Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30. PMID 41319042
Identifiers
NCT: NCT07634016 · 2020-00002